

| | |
|-------------------------|--|
| 1. Record Nr. | UNINA9910811297003321 |
| Titolo | The BMT data book |
| Pubbl/distr/stampa | Cambridge ; ; New York, : Cambridge University Press, 2009 |
| ISBN | 1-107-19285-4 0-511-51773-4 0-511-51511-1 0-511-51419-0 0-511-57552-1 0-511-51639-8 |
| Edizione | [2nd ed. /] |
| Descrizione fisica | 1 online resource (xvi, 526 pages) : digital, PDF file(s) |
| Altri autori (Persone) | MunkerReinhold LazarusHillard M AtkinsonKerry |
| Disciplina | 617.4/40592 |
| Soggetti | Bone marrow - Transplantation Internal medicine |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Previous ed.: 1998. |
| Nota di bibliografia | Includes bibliographical references and index. |
| Nota di contenuto | Cover; Half-title; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Section 1 Basic science; Section 2 Hematologic malignancies; Section 3 Solid tumors; Section 4 Nonmalignant disorders; Section 5 Practical aspects and procedures; Section 6 Complications; Section 7 The BMT/SCT pharmacopoeia; Section 8 HLA-testing and laboratorymedicine; Appendix; Index |
| Sommario/riassunto | The BMT Data Book is an essential guide to the data, outcome studies and complex decision-making processes involved in blood and marrow stem cell transplantation. Organized according to types of diseases and procedures, it contains more than hundred tables, figures and algorithms that reflect up-to-date research and give guidance on the choices between stem cell versus bone marrow transplantation, autologous versus allogeneic transplantation, and conventional versus experimental treatments. This new edition summarizes research of the last 5 years and gives mature data for all established indications, such |

as acute myeloid leukemia, myelodysplastic syndromes, Hodgkin's and Non-Hodgkin's lymphomas. In addition, controversies and new indications - like renal cell cancer and autoimmune disorders - are discussed plus new drugs and therapies, new stem cell sources (cord blood), new transplant protocols (reduced-intensity conditioning), and a guide to electronic databases.
